iPad or detail-Pad – are pharmaceuticals using the real tech-Pad?
Posted 27th April 2012 in Articles, General | Register to comment
Harshit Jain shares his views on the influence of new technology in the pharma industry, specifically looking at iPads and detail pads, and their benefits to healthcare.
A December 2010 Wall Street Journal article stated Abbott Laboratories, Medtronic Inc., and Boston Scientific Corp. were among those in our industry…
Read the full articleTrapped in a regulation labyrinth: The case of the Indian medical device industry (part 2)
Posted 27th April 2012 in Articles, General | Register to comment
Dinar Kale continues to discuss the medical device market in India.
Without any regulation the market was populated by spurious manufacturers and counterfeit traders who used scrap material as…
Read the full articleMarket access strategy
Posted 26th April 2012 in Articles, General | Register to comment
Brian Lovatt and Alan Wilkinson walk us through a successful market access strategy and how early Phase II implementation is key.
Why is it that so many new products have failed to gain access in key markets over the past few years? Indeed, this is a question being asked of the…
Read the full articleExecutive perspectives: Sir Andrew Dillon (part 2)
Posted 26th April 2012 in Articles, General, Interviews | Register to comment
Continuing our market access theme pharmaphorum presents the second part of our video interview with Sir Andrew Dillon, the Chief Executive of NICE.
We recently spoke with Sir Andrew Dillon, Chief Executive of the UK’s National Institute for Health and Clinical Excellence (NICE), which plays a critical role…
Read the full articleExecutive perspectives: Sir Andrew Dillon (part 1)
Posted 25th April 2012 in Articles, General, Interviews | Register to comment
As part of our market access month, pharmaphorum caught up with Sir Andrew Dillon, CEO of the UK’s National Institute of Health and Clinical Excellence, to hear his thoughts.
Assessing the value of new medical interventions and ensuring the appropriate care pathways are in place has become ever more critical as…
Read the full articleThe Future of Healthcare? Kill the bugs save the world! Part 2
Posted 25th April 2012 in Articles, General | Register to comment
In the final part of this 2-part article, Trevor Lewis explores the development of healthcare regulations and his views on the future.
Hopefully, after reading Part 1, readers are left in no doubt about the scale and seriousness of the war that needs…
Read the full articlePharma talent management
Posted 24th April 2012 in Articles, General, Interviews | Register to comment
Gráinne Higgins of Shire pharmaceuticals shares her top tips on successful talent management within pharma in our latest interview.
As we move to an era in which talent capital defines a pharmaceutical organisation’s identity, talent management processes and metrics…
Read the full articleLocal manufacturing – a market access tool for MNCs in Egypt
Posted 24th April 2012 in Articles, General | 1 comment
Nader Rizkalla explores market access in Egypt and gives his thoughts on how local manufacturing can benefit multi-national corporations.
Egypt is recognized as a tier three pharmerging country. The Egyptian pharmaceutical market is a very large market, in terms of volume…
Read the full articlePharma gets social: pharma on Pinterest
Posted 23rd April 2012 in Articles, General | Register to comment
Daniel Ghinn shares his thoughts on how the pharma industry can use up-and-coming social networking site, Pinterest, to their advantage.
Whether it’s just the latest fad or a new phenomenon that’s here to stay, one thing that’s clear about Pinterest, the visual social sharing tool, is that…
Read the full articleAn integrated approach to biosimilar development and commercialization
Posted 23rd April 2012 in Articles, General | Register to comment
Deepa Dahal provides thoughts on the future of the biosimilar industry with respect to market access, our theme on pharmaphorum this month.
Over the next 10 – 15 years, the biosimilars industry is expected to explode as the patents on branded biologics begin to expire.
Read the full article